Top 10 Oncology Capital Raises in the U.S. – April 1st-15th, 2025
Several interesting transactions closed in the Oncology sector over the past two weeks. If you would like more info on these deals or would like to discuss the capital raising market for your company, please contact me.
PIPE
-
- Adaptin Bio, developer of biotechnology solutions focused on developing precision cancer therapies for the brain and other tissues, received approximately $7.7 million of development capital through a private placement.
- Aptevo Therapeutics, a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer, receive $2.1 million of development capital through a private placement.
- Serina Therapeutics, a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain, received $5 million of development capital through a private placement.
Merger/Acquisition and Corporate
-
- Evergreen Theragnostics, operator of contract development and manufacturing platform intended to improve the available options for cancer patients through radiopharmaceuticals, was acquired by Lantheus Medical Imaging for $250 million.
Later Stage VC
-
- Apeximmune, developer of novel biologics designed to modulate the immune system, raised $21.3 million of Series A venture funding in a deal led by PharmaEssentia.
- Lytica Therapeutics, operator of a biotechnology company intended to develop novel peptide conjugates for next-generation Antibody-Drug Conjugates, raised $7.75 million of venture funding in the form of convertible debt from Standish Spring Investments and other investors.
Early Stage VC
-
- Attovia, developer of biotherapeutics pipeline designed for immune-mediated disease and oncology, raised $90 million of venture funding in a deal led by Deep Track Capital.
- Prana Surgical, developer of medical devices designed for minimally invasive surgery, raised $1.5 million of venture funding through a combination of equity and debt financing.
Seed
-
- Daymark Health, provider of supportive care services designed for cancer patients, raised $11.5 million through the combination of debt and Seed funding in a deal led by Maverick Ventures and Yosemite.
- ImmuneBridge, developer of allogeneic cellular immunotherapies designed for advancing cancer treatment, raised $5.63 million through a combination of Seed II, Seed II-A and Seed II-B funding.
#castleplacement #capitalraising #privateequity #venturecapital #investment #Oncology
Gary Levy
Managing Director
Over 30 years in financial services, including senior roles at Citi, Ivy Asset Management (an Affiliate of BNY) and TIAA. Founder and President of Biltmore Savings Consultants, a provider of B2B technology solutions to improve operations. Author of published book "21 Ways to Improve Your Business Operations." MBA - Strategic Business Management from Hofstra University’s Frank G. Zarb School of Business. BS (with a concentration in Business, Management and Economics) from SUNY Empire State College. Series 7, 63 and 79 licenses.
- Email: glevy@castleplacement.com
- (C) (516) 457-0104
Please contact me if you have any questions or would like to discuss your capital raise:
Email: glevy@castleplacement.com
(C) (516) 457-0104
Send us a message:
Sources: Information on this page was derived from a variety of sources including Bloomberg, Company Websites, Crunchbase, PitchBook and other news outlets. Castle Placement™ does not warrant or guarantee this information, nor makes any representations as to the accuracy of the information. For more Risks, see CPGO Risks and Disclaimers.











